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Tissue engineeringIn recent years, the use of bone marrow mesenchymal stem cell (BMSC) implantation has provided an alter-
native treatment for osteoarthritis. The objective of this study is to determine whether or not an intra-
articular injection of a single dose of autologous chondrogenic induced BMSC could retard the progressive de-
struction of cartilage in a surgically induced osteoarthritis in sheep. Sheep BMSCs were isolated and divided
into two groups. One group was cultured in chondrogenic media containing (Ham's F12:DMEM, 1:1) FD+1%
FBS+5 ng/ml TGFβ3+50 ng/ml IGF-1 (CM), and the other group was cultured in the basal media, FD+10%
FBS (BM). The procedure for surgically induced osteoarthritis was performed on the donor sheep 6 weeks
prior to intra-articular injection into the knee joint of a single dose of BMSC from either group, suspended
in 5 ml FD at density of 2 million cells/ml. The control groups were injected with basal media, without
cells. Six weeks after injection, gross evidence of retardation of cartilage destruction was seen in the osteoar-
thritic knee joints treated with CM as well as BM. No signiﬁcant ICRS (International Cartilage Repair Society)
scoring was detected between the two groups with cells. However macroscopically, meniscus repair was ob-
served in the knee joint treated with CM. Severe osteoarthritis and meniscal injury was observed in the con-
trol group. Interestingly, histologically the CM group demonstrated good cartilage histoarchitecture,
thickness and quality, comparable to normal knee joint cartilage. As a conclusion, intra-articular injection
of a single dose of BMSC either chondrogenically induced or not, could retard the progression of osteoarthritis
(OA) in a sheep model, but the induced cells indicated better results especially in meniscus regeneration.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Osteoarthritis (OA) is the most common joint disease in middle
aged and older people and is among the most frequent and symptom-
atic health problems for this age demographic (Schaap et al., 2011;
Brooks, 2002). It is characterized by the degeneration of the articular
cartilage, leading to loss of matrix, ﬁbrillation, formation of ﬁssures,
and ultimately the complete loss of the cartilage surface. To date,
the common treatment focuses on alleviating the pain and thus al-
lows the patient to move and reduces morbidity (Moe et al., 2011;entre, Universiti Kebangsaan





NC-ND license.Magill et al., 2011; Brooks, 2002; Altman, 2009). More recently, phar-
macological treatment with drugs such as chondrotin sulfate, even
though they cannot reduce the symptoms quickly, has proven to
have some structure-modifying effects on the disease area in the
long term (Imada et al., 2010; Uebelhart, 2008). Surgical intervention,
including arthroscopic surgery to remove and stimulate joint repair,
and prosthetic joint replacement, is also a treatment option (Magill
et al., 2011; Steadman et al., 2007, 2003). However, despite the mul-
tiple modalities of treatment, the outcome is still poor and focuses on
temporary measures to alleviate the symptoms rather than treating
the pathogenesis of the disease or focusing on reversing the process
of osteoarthritis.
Since the development of tissue engineering, cartilage cells, better
known as chondrocytes, are one of the ﬁrst such treatments being
studied and manipulated (Langer and Vacanti, 1993; Saim et al.,
2000; Kamil et al., 2002). The ﬁrst clinical application of tissue engi-
neering and cell-based therapy to treat joint and bone defects is
the implantation of autologous chondrocytes (Horas et al., 2003).
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chondrocytes with bioinnert biomaterial has a potential in treating
osteoarthritis (Vijayan et al., 2010; Kreuz et al., 2009; Hollander
et al., 2006; Ossendorf et al., 2007).
Even though the clinical application of chondrocyte implan-
tation has been quite popular and has been aggressively pursued in
recent years, other potential cells, such as the mesenchymal stem
cells (MSCs) and in particular BMSC, became more popular (Madry
and Cucchiarini, 2011). The interest in these cells came from a study
reported by Murphy et al. (2003), where intra-articular injection
of BMSCs was used in an OA goat model. Since then, several clinical
trials have been performed using a similar technique and have
shown promising results (Maumus et al., 2011; Centeno et al., 2008;
Wakitani et al., 2002; Csaki et al., 2008).
The use of BMSC not only provides an alternative cell candidate,
but may also allow for manipulation to provide the best and most
ideal cells for implantation. This manipulationwas initiated by examin-
ing the inductionmedia. It has been shown that induction using growth
factors, such as transforming growth factor (TGF) and insulin like
growth factor (IGF), signiﬁcantly inﬂuences the quality of the chondro-
cytes (Huang et al., 2012; O'Sullivan et al., 2011; Indrawattana et al.,
2004; Chua et al., 2007, 2005, 2004). MSCs cultured with TGF-β3 for
2 to 3 weeks were shown to stimulate proteoglycan and collagen type
II synthesis, both of which are characteristic of hyaline articular
cartilage (Indrawattana et al., 2004). On the other hand, many of the
components of a cartilaginous extracellular matrix are deposited by dif-
ferentiating MSCs exposed to TGF-β3, including aggrecan link protein
and type II collagen (Mi et al., 2000). Chondrogenic differentiation
occurs when MSCs are grown under conditions that include a three-
dimensional culture format, serum-free nutrient medium and the addi-
tion of TGF-β (Ng et al., 2008; Cao et al., 2012). When these conditions
aremet, the cells rapidly lose their ﬁbroblasticmorphology and begin to
initiate the expression of a number of cartilage-speciﬁc extracellular
matrix components (Lum et al., 1996). During differentiation in the
presence of TGF-β3, MSCs synthesize aggrecan link protein, ﬁbromodu-
lin, cartilage oligomeric matrix protein, decorin, type II collagen and
chondroadherin, all of which are components of the normal articular
cartilage matrix (Moulharat et al., 2004).
With the advancement of growth factors and the manipulation of
in vitro induction, it is important to study the effect of these factors in
a big animal study. In this study the induction using chondrogenic
medium was prepared according to our previous study (AlFaqeh
et al., 2011). After inducing OA in sheep model, the chondrogenic in-
duced BMSCs were injected intra-articularly. The sheep were sched-
uled for a required exercise regime and sacriﬁced after 6 weeks. The
results will be observed via histological examination of the affectedBM at day 20
A
Fig. 1. Morphology of cells cultured in monolayer. Day 20 BM group formed dense
(B). Magniﬁcation ×40.joints and compared to control. We do hope this study will be a refer-
ence to our future ﬁrst phase clinical trial.2. Material and methods
2.1. Osteoarthritis induction in sheep
The study was conducted after an approval from the Universiti
Kebangsaan Malaysia Animal Ethical Committee. A total of sixteen
(Siamese long tail) (Universiti Putra Malaysia) sheep were involved
in the study. Each was aged between 11 and 12 months old with an
average weight of 25 kg. The sheep were randomized into three
groups of six animals each, with the exception of the control group
that consisted of 4 sheep. No differences were observed between
the control group and the test groups with respect to age and weight.
For the induction of osteoarthritis (OA) the sheep underwent a bone
marrow aspiration for cell preparation on the same day of the surgical
procedure. The surgical protocol was conducted according to previous
methods described by Murphy et al. (2003) with some modiﬁcation.
In the anesthetic procedure, the animals were induced by intravenous
injection of xylazine (0.1 mg/kg) and ketamine (5 mg/kg) and main-
tained with isoﬂurane (1.5%) in oxygen, delivered by an endotracheal
tube (Troy Laboratories Australia).
A lateral parapatellar skin incision was made beginning at a level of
2 cm proximal to the patella and extending to the level of the tibial pla-
teau. The subcutaneous tissue was incised, and the lateral fascia was
separated for 1 cm from the joint capsule in either direction from the in-
cision. The lateral aspect of the vastus lateralis and the joint capsule
were incised, and the patella was luxated medially to expose the troch-
lear groove and medial and lateral condyles of the distal femur.
ACL excision was performed by ﬁrst excising its attachment on the
medial aspect of the lateral femoral condyle. The proximal attach-
ment was brought forward and the entire ligament was excised
from its tibial attachment. The stiﬂe was moved in a drawer test to
ensure that the entire cruciate ligament had been excised.
In the medial meniscus removal, meniscus was removed by sharp
excision. The caudal horn of the meniscus was grasped with a hemo-
stat, and its axial (lateral) attachment was excised from its tibial at-
tachment. Working from caudal to lateral and then cranial, the
meniscus was excised from its attachments until it was completely
removed. Postoperatively the sheep were observed and monitored
for 24 h in an animal intensive area. All the vital signs were observed
and after 24 h the sheep were placed in an animal house.
After a recovery period of 3 weeks, all animals were made to run
on a hard surface for a distance of 100 m, once daily for 3 weeks. AtCM at day 20
B
monolayer cells (A) and CM group exhibited cell aggregation forming colonies
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ﬁned environment.
2.2. Cell isolation and culture
Five to ten milliliters of bone marrow aspirate was drawn from the
iliac crest of a sheep (n=12) using a Jamshidi-bone marrow aspiration
needle (Cardinal Health Inc, USA) in a 20 ml heparinized sterile syringe
(Cringe, Malaysia). The BMSCs were isolated from the aspirated bone
marrow via gradient centrifugation (Universal 32 R, Germany) over a
Ficoll-Paque PLUS layer (Healthcare, Sweden), at 3000 rpm equivalent
to 1400 g for 30 min, and subsequently washed twice with phosphate








Fig. 2. Gross evaluation of the OA knee joint 6 weeks after intra-articular injection. Gross mo
idence of repair (2A). The meniscus was entirely damaged in the control group (2B). Joint
(2C). The meniscus showed evidence of scarring in BM group (2D). Joint injected with CM sh
the meniscus like tissue was observed in CM group (2F). Normal contralateral knee joint (2culture medium FD (Ham's F12:high glucose DMEM 1:1; GIBCO, USA)
supplemented with 10% fetal bovine serum (GIBCO), 1× antibiotic–
antimycotic (GIBCO), 1× GlutaMAX-1 (GIBCO), 50 μg/ml L-ascorbic
acid (Sigma), 0.02 MHEPES buffer (GIBCO), and plated in 25 cm2/plastic
culture ﬂasks. The cells were incubated at 37 °C in a humidiﬁed
atmosphere containing 5% CO2. The medium was changed every 2 to
3 days. On days 8 to 10, the cells reached conﬂuence and were then de-
tached with 0.25% Trypsin/0.1% EDTA (GIBCO) and recultured as the
ﬁrst passage with FD+10% fetal bovine serum (FD/FBS). When the
cells reached 80% conﬂuence, they were trypsinized and cryopreserved.
Brieﬂy, the cell pellet was suspended in 1 ml of DMSO+FBS 20%









rphology of the control (basic media) group showed severe OA lesion without any ev-
injected with BM showing some evidence of repair and healing of the cartilage surface
owing a smaller lesion with smooth edges (2E). A signiﬁcant amount of regeneration of
G and 2H).
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Frozen cells at passage 2were thawed 3 weeks before intra-articular
injection by immediately placing them in a water bath at 37 °C.
They were then washed two times with a phosphate buffer solution
(1× PBS) containing antibiotic/antimycotic. The cells were then divided
into two groups. Group CM was suspended in FD, 1% FBS, 1% ITS
(GIBCO), 50 μg/ml ascorbic acid-2 phosphate, 40 ng/ml L-praline,
1×10−4 mM dexamethasone, 5 ng/ml transforming growth factor
beta 3 (TGF-β3), and 50 ng/ml insulin like growth factor 1(IGF-1)
according to a previous study (AlFaqeh et al., 2011). Group BM was
suspended in FD supplemented with 10% FBS and plated in T-75 cm2
cell culture ﬂasks. All cells were incubated at 37 °C in a humidiﬁed
atmosphere containing 5% CO2 and the medium was changed every
3 days.2.4. Intra-articular injection of BMSC
After 3 weeks in culture (passage 2), the cells were trypsinized,
washed with PBS and suspended in FD at a density of 2×106 cells/ml.
The sheep were anesthetized, intubated, and placed in dorsal recum-
bency. The test animals received a single intra-articular injection into
the osteoarthritic knee joint of the sheep using an 18-gauge needle of
10 million cells (2 million/ml FD). The needle was inserted posterior
to the medial edge of the patellar ligament, through the triangle
formed by the epicondyle of the femur, after which the synovial ﬂuid
was aspirated. The control animals (control) received an injection of
the same volume of FD without cells. Following the injection, the
joint was repeatedly ﬂexed and extended to disperse the suspension
throughout the intra-articular space. All animals were kept under clini-
cal observation for 6 weeks and later sacriﬁced. The distal head of the
femur as well as the proximal head of the tibia plateau of both the













es2.5. Gross and histological analysis
After 3 weeks post surgery the animals were sacriﬁced. The knee
of the experimental sheep and contra-lateral joints were dissected
and examined macroscopically by two independent (blinded) exam-
iners. Macroscopic observations were done in accordance with the In-
ternational Cartilage Repair Society (ICRS) cartilage repair assessment
system. Using the above system the assessment was recorded using
macroscopic examination on the surface of the cartilage. Overall re-
pair assessment was scored and later graded, from normal (grade 1)
to severely abnormal (grade 4).
The femoral condyle and proximal tibia were bisected in saggital
plane sections of the operated medial and contra-lateral head of the
femur and the distal head of the tibia, using a diamond saw. All spec-
imens were ﬁxed in 10% formalin buffer at 4 °C for 48 h and then de-
calciﬁed in 0.5 EDTA containing 8% hydrochloric acid for 3 to 4 weeks,
with the decalciﬁcation solution changed every week. The specimens
then underwent automated tissue processing for 24 h using a tissue
processor (Leica TP-1020, Germany). Sections were imbedded in
parafﬁn and cut into 5 μm slices. Each section was then stained with
haematoxylin and eosin (H&E) and safranin O.0
Control BM CM
Fig. 3. The grading of the joints using the ICRS grading system. The control group
scored 3.4±0.38 points, the CM group scored 0.8±0.35 points and the BM group
scored 1.22±0.89 points. Scores were compared by analysis of variance. There were
signiﬁcant differences between CM and control, ** pb0.05 and between BM and con-
trol, * pb0.05. No signiﬁcant difference was detected between both groups treated
with cells (CM and BM).2.6. Statistical analysis
Comparisons of the histology scores between groups were made
using the Mann–Whitney test as it is the most suitable descriptive
and non-parametric test. A p value of less than 0.05 between groups
was considered signiﬁcant.3. Results
3.1. Morphology observation of sheep BMSC in in vitro culture
The BM group showed obvious spindle bipolar to polygonal cells
attached to the ﬂask after 4 days of culture. After day 12, the culture
reached conﬂuency and formed a dense monolayer of adherent cells
(Fig. 1A). In contrast, the CM group grew as cell aggregates and
after day 12 formed larger aggregates (Fig. 1B).
3.2. Clinical observations
There was no evidence of infection in any of the animals before
and after the experiments. All animals bore weight after surgery.
The animals tolerated the cell injection well, and there was no evi-
dence of local inﬂammation or immobilization of the joint from the
cell injection.
3.3. Macroscopic observations post surgery
3.3.1. Cartilage lesion
Changes to the femoral condyle in CM, BM and control groups
after 6 weeks of exposure, were independently assessed with regards
to articular lesions using the ICRS grading system. Quantitatively, all
femoral distal heads and many of the medial plateaus from the
meniscectomy knees of the sheep had osteoarthritis. The highest
lesion score, 3.44±0.38 points, was observed in the control group
(Fig. 2A). On the other hand, the knee joints that received BM showed
a smaller lesion of the femoral condyle compared to the control
group, demonstrating scores of 1.22±0.89 points (Fig. 2E). The less
cartilage lesion scores of 0.8±0.35 points were observed for the
knee joints that received CM, the lesion was shallow and exhibited
smooth edges (Fig. 2C).
The ICRS scores were compared by analysis of variance and reveal
no signiﬁcant difference between the CM and BM groups (Fig. 3).
However, these two groups have a signiﬁcant difference when com-
pared to the control group (Fig. 3).
3.3.2. Meniscus lesion
The BM and control samples showed a damage and absence of me-
niscus, respectively (Fig. 2B and D). However in the CM group there is
an appearance of meniscal-like tissue formation at the surgical site
(Fig. 2F).
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3.4.1. Cartilage
The joints that were injected with BM exhibited cartilage loss
almost exposing the bony layer, and showing no evidence of regener-
ation, (Fig. 4A and B). In this group there was substantial ﬁbrillation
of the articular surface with loss of the extracellular matrix as well
as large areas of osteophytic remodeling. The BM group displayed
reasonable cartilage regeneration when compared to normal contra-
lateral knee joint, (Fig. 4C and D). The CM group also demonstrated
reasonable cartilage surface comparable to normal contralateral
knee joint (Fig. 4E and F). The superﬁcial area was smooth without
any evidence of inﬂammation and almost similar cartilage thickness
to the normal knee, (Fig. 4G and H).3.4.2. Meniscus
The H&E staining showed presence of cells and ﬁbrous tissue in







Fig. 4.Microscopic analysis by H&E (4A, 4C, 4E and 4G) and Safranin-O (4B, 4D, 4F and 4H)
that were injected with basic medium (control) exhibited cartilage loss almost exposing th
moderate cartilage repair but the cartilage thickness is less than normal knee joint (4C and
to normal knee joint (4E and 4F). There was no sign of OA in the contralateral knee joint (ﬁbrocartilage as in native meniscus even though the cell looks imma-
ture with large nucleus (Fig. 5).4. Discussion
Mesenchymal stem cells have become a promising and fascinating
biological approach for cartilage repair. The present study evaluated
the utility of stem cell therapy in retarding the progression of osteo-
arthritic lesions that occur following knee joint injury. Six weeks
after total medial meniscectomy and resection of the ACL, CM and
BM were delivered by an intra-articular injection. In this study, no
biomaterial or additional chemicals were used to ensure that clear
results from the stem cell therapy in the osteoarthritic knee joint
could be observed.
For the induction of osteoarthritis, the ACL ligament and meniscus
must be excised. Postoperatively the sheep must undergo normal
movement to simulate the continuous trauma and repair as observed







staining of the sheep femoral condyle 6 weeks post intra-articular injection. The joints
e bony layer, and showing no evidence of repair (4A and 4B). The BM group displayed
4D). The CM group demonstrated good cartilage phenotype with thickness comparable
4G and 4H). Original magniﬁcation ×40.
A B50µm 50µm
Fig. 5.Microscopic analysis by H&E of the meniscus-like tissue in CM group. The histology showed the presence of ﬁbro tissue with cells (5A) resembling ﬁbrocartilage structure as
in native meniscus (5B). Original magniﬁcation ×40.
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on OA treatment utilizing cell therapy (Van den Borne et al., 2007).
The effect of osteoarthritis was not only seen on the cartilage sur-
face, but also on the meniscus site. In the CM group, the results
showed a formation of meniscus like structure at the site of surgery.
The histology showed cartilage-like cells with big nucleus resembling
an immature tissue and possibly given a longer time it might turn
into a mature ﬁbro cartilage similar to native meniscus. At present,
the surgical repair of the meniscus is via the removal of the damaged
area with or without a graft (Jarit and Bosco, 2010; Stärke et al., 2009;
Gomoll et al., 2009; Beauﬁls et al., 2009). All of the grafts used were
either synthetic or non-synthetic without any regenerative advan-
tage. With the injection of CM, as shown in this study, it is possible
to regenerate the meniscus.
For the osteocartilage surface, both groups that were treated
with cells demonstrated potential regeneration of cartilage and thus
retarding the progress of OA. Even though the CM group did not dem-
onstrate any signiﬁcant differences compared to the BM group, the
ICRS score is slightly higher.
Previous in vitro studies have shown that the inductionmedia con-
taining bioactive factors, such as transforming growth factor family
(TGF-β) insulin like growth factor 1 (IGF-1) and dexamethasone, pro-
mote the synthesis of proteoglycans without signiﬁcantly affecting in-
ﬂammation or cartilage breakdown (Chubinskaya et al., 2011; Mi
et al., 2000; Lum et al., 1996; Moulharat et al., 2004). TGF-β is capable
of increasing proteoglycan synthesis by neutralizing interleukin-1b
(IL-1b), which is responsible for the suppression of proteoglycan syn-
thesis (Cheng et al., 2010; Lum et al., 1996). This effect was seen in our
in vitro culture experiments, in which BMSC grown in chondrogenic
medium containing TGF-β3, IGF-1 and dexamethasone for 3 weeks
began to form colonies and aggregated, in contrast to cells seeded in
basic medium, which formed multilayered cells.
The concept of injecting BMSC to treat OA is not new and has
been the subject of many clinical trials for the last decade (Madry
and Cucchiarini, 2011; Centeno et al., 2008). The results are quite
promising, but they usually depend on the institution (Pak, 2011;
Kasemkijwattana et al., 2011). BMSCs have the ability to suppress im-
munity and prevent rejection by suppressing the local immune re-
sponse and preventing scar formation (Caplan and Dennis, 2006).
Interestingly, studies have shown that BMSCs derived from a patient
with OA are able to produce matrix and even able to express the
collagen type II marker upon induction with TGF-β3 (Kaﬁenah et al.,
2007; Ringe et al., 2007). A worldwide multicenter clinical trial
reported encouraging results on BMSC implantation (Wakitani et al.,
2002; Marcacci et al., 2007; Verbruggen et al., 2007; Pak, 2011;
Kasemkijwattana et al., 2011). Unfortunately it is quite difﬁcult to
standardize the outcome. Most of the studies above were done
using cell therapy using undifferentiated BMSC together with surgical
treatment. This is an important oversight, since BMSCs are multipo-
tent cells that can potentially create uncontrolled cell regeneration
in cells such as osteoblast, ﬁbroblast or even neuroblast if injected
without induction to a speciﬁc cell linage. This is very possible in a
damaged joint, such as one with traumatic osteoarthritis, which con-
tains multiple growth factors (Barthel et al., 2009). It might be theexplanation for why the clinical outcome differs from one center to
another. In this study, no surgical intervention was done, only cell
therapy. To date, only one case that has been reported by Centeno
et al. (2008) relied solely on a percutaneous injection of BMSC ex-
panded in vitro with normal basal medium. From the ﬁnding of our
study there is an advantage in using induced BMSC over BMSC
alone especially after seeing the effect on the meniscus and the possi-
bilities of reducing the morbidity of OA patient.
The next step would be the ﬁrst phase clinical trial. We do under-
stand that it would be a daunting task as we would be facing a strin-
gent ethical guideline and expansive in vitro cell preparation
requirement. Nevertheless, this study has shown the potential of
BMSC injection for the treatment of OA, with the induction media
displaying better results on meniscus repair. Most importantly, with
the increase in worldwide human clinical trials, we hope that this
study will serve as a reference for the patients and clinicians involved.
5. Conclusion
From our ﬁndings it is suggested that an intra-articular injection
into OA knee joints of sheep with autologous bone marrow stem
cells cultured in chondrogenic medium has the possibility of retard-
ing the progression of OA.
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